UNSPSC 51162746: Tyloxapol

This classification denotes a surface-active agent with the molecular formula (C15H22O(C2H4O)n)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y27PUL9H56, chemically known as 4-(1,1,3,3-tetramethylbutyl)phenol, polymer with formaldehyde & oxirane but more generally known as tyloxapol, which bears US NIH Compound Identifier 71388. European Medicines Agency schedules Tyloxapol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05015MIG.

World Health Organization schedules tyloxapol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, TYLOXAPOL remains US FDA's Preferred Term for this commodity. Tyloxapol bears US NLM identifiers UMLS ID C0077539 and NCI Concept Code C80949. SMILES: CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1.

UNSPSC 51162746 Tyloxapol is a Commodity code covering pharmaceutical and chemical products used in state and local health and safety applications. Recent solicitations under this code show state and local governments procuring naloxone (an opioid-antagonist medication) and related drug-deactivation systems for community health initiatives, as well as participating in multistate cooperative purchasing agreements for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to government facilities. The issuing bodies include county health departments and multistate cooperative purchasing alliances administered by state procurement offices. County governments, typically through their health or community services divisions, issue individual IFBs for specific pharmaceutical products and medical supplies. Multistate cooperatives, such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), consolidate demand across participating state and local jurisdictions and use RFPs to establish framework agreements with multiple manufacturers, who then supply products through authorized wholesalers.

Recent activity centers in Florida and Minnesota, with the Minnesota procurement serving as a multistate vehicle spanning Oregon and other participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building. The Minnesota Department of Administration's Office of State Procurement, acting through MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, effective July 1, 2026. Both procurements require vendors to meet cGMP compliance, maintain specified insurance coverage, and comply with federal requirements including FDA standards and Drug Supply Chain Security Act certification. Vendors must provide detailed product information including NDC codes and manufacturing locations, and pricing is weighted heavily in evaluation (75 percent in the MMCAP RFP). No explicit set-aside designations are documented in either solicitation.